CINECA IRIS Institutional Research Information System

DURELLI, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.235
EU - Europa 9.152
AS - Asia 7.310
SA - Sud America 1.011
AF - Africa 306
OC - Oceania 50
Continente sconosciuto - Info sul continente non disponibili 42
Totale 29.106
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.966
SG - Singapore 3.064
IT - Italia 2.157
CN - Cina 1.877
DE - Germania 1.533
FR - Francia 878
IE - Irlanda 846
VN - Vietnam 837
BR - Brasile 826
UA - Ucraina 783
SE - Svezia 740
FI - Finlandia 632
KR - Corea 601
GB - Regno Unito 486
PL - Polonia 261
AT - Austria 220
HK - Hong Kong 195
IN - India 179
CA - Canada 172
SN - Senegal 134
RU - Federazione Russa 132
NL - Olanda 117
DK - Danimarca 112
JP - Giappone 97
IQ - Iraq 79
MX - Messico 68
AR - Argentina 60
BD - Bangladesh 59
ID - Indonesia 47
ES - Italia 41
GR - Grecia 40
ZA - Sudafrica 40
AU - Australia 37
EU - Europa 37
EC - Ecuador 36
BE - Belgio 35
TR - Turchia 33
MU - Mauritius 26
UZ - Uzbekistan 26
IR - Iran 25
CO - Colombia 24
PK - Pakistan 24
CL - Cile 22
PH - Filippine 18
EG - Egitto 17
MA - Marocco 17
SA - Arabia Saudita 17
VE - Venezuela 17
JO - Giordania 16
CZ - Repubblica Ceca 15
KE - Kenya 15
TN - Tunisia 15
IL - Israele 14
LT - Lituania 13
RO - Romania 13
AL - Albania 12
AZ - Azerbaigian 12
CH - Svizzera 12
NO - Norvegia 12
NZ - Nuova Zelanda 12
NP - Nepal 11
BG - Bulgaria 10
PE - Perù 10
PT - Portogallo 10
TH - Thailandia 10
LB - Libano 9
KG - Kirghizistan 8
UY - Uruguay 8
BH - Bahrain 7
DZ - Algeria 7
ET - Etiopia 7
HU - Ungheria 7
MY - Malesia 7
AE - Emirati Arabi Uniti 6
DO - Repubblica Dominicana 6
OM - Oman 6
PY - Paraguay 6
HR - Croazia 5
RS - Serbia 5
TT - Trinidad e Tobago 5
TW - Taiwan 5
CI - Costa d'Avorio 4
HN - Honduras 4
SK - Slovacchia (Repubblica Slovacca) 4
SY - Repubblica araba siriana 4
BY - Bielorussia 3
CR - Costa Rica 3
EE - Estonia 3
JM - Giamaica 3
MD - Moldavia 3
NG - Nigeria 3
PA - Panama 3
SC - Seychelles 3
SI - Slovenia 3
TG - Togo 3
BA - Bosnia-Erzegovina 2
BW - Botswana 2
CY - Cipro 2
GA - Gabon 2
KH - Cambogia 2
Totale 29.062
Salva come PNG Salva come JPEG
Città #
Singapore 1.598
Chandler 1.111
Beijing 1.085
Dublin 838
San Jose 685
Ashburn 654
Ann Arbor 541
Jacksonville 431
Houston 415
Santa Clara 392
Medford 344
Villeurbanne 320
Princeton 305
The Dalles 291
Milan 282
Columbus 269
Fremont 258
Warsaw 255
Los Angeles 249
Lauterbourg 247
Dearborn 246
Ho Chi Minh City 237
Fairfield 231
Wilmington 225
Nyköping 222
Torino 197
Vienna 194
Buffalo 188
Hanoi 171
Dallas 167
Hong Kong 164
Turin 154
Rome 145
Woodbridge 137
Boston 125
Munich 123
Dong Ket 106
Seoul 104
Verona 95
Hefei 90
New York 86
Guangzhou 83
Boardman 82
Tokyo 72
São Paulo 69
Seattle 64
Cambridge 58
Redwood City 56
Helsinki 55
Toronto 54
Falls Church 50
Pisa 49
Frankfurt am Main 47
Norwalk 47
Düsseldorf 44
Catania 42
Lachine 40
London 40
Orem 40
Turku 39
Palermo 37
Council Bluffs 36
Nuremberg 36
Da Nang 34
Nürnberg 34
Washington 34
Rio de Janeiro 32
Baghdad 31
Nanjing 31
Haiphong 30
Florence 29
Amsterdam 28
Montreal 27
Jakarta 26
Naples 25
Belo Horizonte 23
Brussels 23
Chennai 22
Phoenix 22
Shanghai 22
Jinan 21
Redondo Beach 21
Bologna 20
Brasília 20
Johannesburg 20
San Diego 20
Seongnam 19
Bari 18
Curitiba 18
Manchester 18
Kunming 17
Menlo Park 17
Paris 17
Pune 17
Redmond 17
San Mateo 17
Amman 16
Campinas 16
Chicago 16
Hangzhou 16
Totale 15.951
Salva come PNG Salva come JPEG
Nome #
Il Bergamini di Neurologia 1.484
Randomized trial of thymectomy in myasthenia gravis 667
Pregnancy epigenetic signature in T helper 17 and T regulatory cells in multiple sclerosis 454
Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis 429
Computer assisted interactive learning in medical education: flipped classrooms of clinical neurology for medicine students 405
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial 385
Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months 262
Alemtuzumab Long Term Immunological Study: The Immunosuppressive Effect Does Not Last More Than 48 Months 241
T helper subsets changes in alemtuzumab multiple sclerosis treated patients: the recovery of immune system capacity as a possible indicator to treatment 229
Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: Findings from an Italian independent registry 225
A new T helper subset producing Interleukin 22 increases in multiplesclerosis patients. 211
Lack of CD4 + T cell percent decrease in alemtuzumab-treated multiple sclerosis patients with persistent relapses 210
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study 196
In Human Multiple sclerosis, T helper 17 lymphocytes display increased levels of JAK2 that stabilize cell surface IFN-YR2chain 195
Natalizumab in Multiple Sclerosis: Long-Term Management 189
How do Treg cell function and related cytokines levels change in alemtuzumab treated patients? A 24 months immunological study 179
Treatment response to interferon beta: Biological (MxA protein or IL-10 mRNA level) or MRI indicators? 173
Alemtuzumab treatment in MS how do the Treg cell function and suppressor cytokine mRNA (IL-10, TGF-beta, IL_27) levels change? 24-month immunological report during 323 and 324 genzyme trials 169
Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report 166
T-Helper (Th)22, a Newly Identified Lymphocyte Subset, Increases 1-3 Months before an MS Relapse and It Is Not Sensitive to IFN beta 165
Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV study. 165
Treatment of multiple sclerosis patients after 24 Natalizumab doses: a prospective observational study: the TY-STOP 160
A 4-year multicenter follow-up of neutralizing anti-interferon antibodies in ms patients treated with high dose (375 mcg) interferon beta-1b 159
La riduzione della dose di ifn beta: “the switch dose study” 158
A comparison of fully automatic and semi-manual contouring software for quantitative magnetic resonance imaging of lesion load in multiple sclerosis 157
Alemtuzumab long-lasting immunological effects: a 48 months follow-up observation 156
A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis 154
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea 151
A 4-year study of anti-interferon neutralizing antibodies in relapsing-remitting multiple sclerosis patients treated with different doses of interferon beta-1b 149
Circulating T helper 22 cells increase in multiple sclerosis patients:phenotypical and functional characterization. 147
Cytomegalovirus reactivation during alemtuzumab treatment in a patient with multiple sclerosis 147
T helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β 144
Adherence to interferon-beta treatment and results of therapy switching 144
Estrogen receptor alpha role in multiple sclerosis patients: trying to identify a new biomarker of disease activity 144
T HELPER 22 CELLS INCREASE IN MULTIPLE SCELROSIS PATIENTS: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION 143
Estrogen receptor-alpha regulates epigenetic changes on genomic regulatory regions: potential biomarkers in multiple sclerosis outcomes 143
Estrogen receptor alpha in peripheral blood lymphocytes of multiple sclerosis patients: a pivotal study of its role in pregnant patients 142
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab 142
Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study. 141
T Regulatories (Tregs) and suppressor cytokine mRNA (IL-10, TGF-beta, IL-27) increase after Alemtuzumab in MS: First 25 Month Immunological Report on 323 and 324 Genzyme trials 141
Chromatin remodeling in Th17 and Treg plasticity induced by E2 immunomodulation 140
T HELPER 22 CELLS INCREASE IN MULTIPLE SCLEROSIS PATIENTS: PHENOTYPICAL AND FUNCTIONAL CHARACTERIZATION 139
Estrogen Receptor Alpha- Associated Genomic Regions Are Potential Core of T Cell Subtypes Identity 139
Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab 139
Gut microbiota alteration in Clinically Isolated Syndrome: a pilot study 138
Follow-up of psychological features in patients treated with botulinum toxin type A 137
Epigenetic therapy for Friedreich ataxia. 134
Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course 134
Prophylaxis of chronic migraine with OnabotulinumtoxinA: experience and evidence in clinical practice 133
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 133
Impact on mental symptoms of botulinum toxin type A therapy in patients affected by focal dystonia and spasticity: preliminary results 132
A Meta-Analysis Of Methylprednisolone In Recovery From Multiple Sclerosis Exacerbations 132
Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD). 132
TYPE 1 INTERFERON RECEPTOR (IFNA-R1). EXPRESSING TH17 LYMPHOCYTES ARE INCREASED DURING MS RELAPSES AND ARE SELECTIVELY INTHBITED BY IFNβ 131
Anti-interferon neutralising antibody occurrence in relapsing remitting ms patients treated with a ifn beta-1b dose higher than the standard one: long-term evaluation 131
A multicentre trial comparing two different doses of ifn beta-1b. the optimization of interferon for ms (optims) study. 131
How to treat patients after natalizumab discontinuation: the TY-STOP 2 study, an Italian, prospective and multicenter study 129
A case of canomad (chronic ataxic neuropathy, ophthalmoplegia, igm paraprotein, cold agglutinins and disialosyl antibodies) with transient cognitive impairment. 128
The Real Life Impact of Early Versus delayed Treatment of Interferon beta on Long Term Disability Progression i relapsing-Remitting Multiple Sclerosis 128
Long Term immunological alemtuzumab effect: increase in Tregsuppressor function 127
Anti-Gm1 And Anti-Sulfatide Antibodies In Polyneuropathies. Threshold Titers And Accuracy 126
Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial 126
Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients. 125
Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a 125
Peritoneal Dialysis and platelet infusion can be effective for MNGIE relapsing neuropathy not responding to intravenous high-dose gammaglobulin (IVIG) 123
Th17, an effector T Lymphocyte subset associated with multiple sclerosis (MS) relapses: antigen specificity, cytokine production, and sensitivity to interferon beta 123
Atypical presentation of superficial sclerosis successfully treated with iron chelation 123
Correlation of anti-interferon beta neutralising antobodies with clinical response and mri activity in the INCOMIN (independent comparison of interferon) trial. 121
Botulinum toxin A (Dysport) for treatment of sialorrhea in patients with neurologic disorders. 121
Estrogen Receptor Alpha Regulates Key Genomic Regions of Thelper 17 and T Regulatory Cells in Multiple Sclerosis: A New Potential Biomarker of Disease Activity 121
A case of Hyperekplexia with positive anti GlyR antibodies: PERM syndrome 120
Early diagnosis of progressive multifocal leucoencephalopathy: Longitudinal lesion evolution 120
A.S.P.I.R.E. (AZATHIOPRINE SECONDARY PROGRESSIVE INTERFERON TREATED PATIENTS RANDOMIZED EVALUATION) study: baseline data from a 2-years double blind, randomized, multicentre, pilot study. 119
Natalizumab Therapy, How to Treat How to Stop: The TY-STOP Study 119
can the increase of T-helper 17 Lymphocyte percentage in peripheral blood anticipate a relapse in relapsing remitting multiple sclerosis? 118
Cytokines and Chemokine mRNA in perpheral blood of multiple sclerosis patients correlates with treatment response and interferon beta dose 118
Atypical Presentation of Progressive Multifocal Leukoencephalopathy in a Natalizumab-treated Patient 118
A COCHRANE review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to Multiple Sclerosis 117
T-helper 17 lymphocytes increase during multiple sclerosis relapses and are inhibited by interferon beta 117
Estrogen receptor alpha regulates key genomic regions of t-helper 17 and T-regulatory cells in Multiple Sclerosis: a new potential biomarker of disease activity. 117
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy 117
Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study 116
Clinically isolated syndrome: when to treat? A Cochrane analysis 115
Treg Cell Function and Related Cytokines and Chemokines Changes during Alemtuzumab Treatment: a 24 Months Immunological Study 115
T helper 17 Lymphocytes and multiple sclerosis: their increase in active phases of disease and the interferon beta induced inhibition 114
Psychological evaluation of quality of life in seizure-free epileptic patients 114
T-helper 17 lymphocytes during MS relapses: antigen specificity and cytokine production. A multicentre longitunal study 113
How to treat MS patients after the 24th natalizumab administration: the TY-STOP trial 113
A COCHRANE meta-analysis on the efficacy of recombinant interferon beta in preventing conversion of clinically isolated syndromes 112
Assessing treatment response to immunomodulatory drugs for ms: a single active mri scan after 6 months of treatment is the best indicator of persisting disease activity 112
Evaluation of mitochondrial manganese in leukocyte of multiple sclerosis patients. 112
The OPTimization of Interferon for MS Study: 375 μg interferon beta-1b in suboptimal responders 112
Autoimmunity profile in interferon beta- 1a treated Multiple Sclerosis patients. the auprin study: comparison of 2 different dosage of subcutaneous interferon-beta 1a 111
T-helper (Th) 22, a newly identified lymphocyte subset, increases 1-3 months before an MS relapse and it is not sensitive to INF beta 111
The still under-investigated role of cognitive deficits in PML diagnosis 111
Immunoglobulin treatment of multiple sclerosis: future prospects. 109
Comparison of immunomodulatory treatments for multiple sclerosis. 109
Autoimmunity profile in interferon beta- 1a treated multiple sclerosis patients. the auprin study: comparision of 2 different dosage of subcutaneous interferon-beta 1a. 108
High-dose intravenous immunoglobulin G treatment of myasthenia gravis. 107
Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS. 107
Totale 16.943
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.874
article - articoli 0
book - libri 0
conference - conferenze 54.651
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 145.525
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021407 0 0 0 0 0 0 0 0 0 0 173 234
2021/20222.458 57 55 86 143 100 137 155 135 87 255 456 792
2022/20233.420 426 232 71 367 270 946 283 217 315 75 156 62
2023/20241.333 147 215 63 101 88 184 29 48 4 85 92 277
2024/20254.035 48 160 140 454 840 190 93 181 546 232 368 783
2025/20267.869 741 367 706 1.172 961 518 1.352 426 700 748 178 0
Totale 30.040